The FBI is investigating Johnson & Johnson's morcellator; Sanofi purchased another priority review voucher; generic drug prices are falling at a slow rate
The pharmacy benefits manager wants oncology treatments priced according to how well they treat a specific cancer as opposed to using the current one-price-fits-all approach.
Experts say Afrezza's tepid launch may have more to do with value proposition than product positioning.
A court halted the launch of Sandoz's biosimilar; GSK said it is concerned about Advair competition in the US; an FDA panel is expected to vote on a female sexual disorder drug
Amgen raises price of Enbrel by 10%; pharma companies appear to raise diabetes drug prices in tandem; Alexion agrees to buy rare-disease drugmaker for $8.4 billion
Worldwide spending on cancer medications hit $100 billion last year; Bayer adds an anticoagulant to its pipeline for $100 million; GlaxoSmithKline has a new chairman
Merck said Januvia is not linked to higher heart-failure risk; Biogen plans to spend $2.5 billion on Alzheimer's disease; Mylan rejected Teva's bid
Teva proposes acquisition of Mylan; start-up offers BRCA testing for $249; Botox receives another label expansion
Americans spent 13.1% more on prescription medications in 2014 than they did in 2013, but recent launches indicate competition in the specialty drug space is going to heat up.
Researchers say countries that spend the most on cancer care have better outcomes, but the explanation behind improved mortality is not clear.
The study will include DTC and DTP advertising.
An American Society of Clinical Oncology report shows the organization wants healthcare professionals to think in terms of value.
A Florida Congressman introduced a bill that would expand patent protections; Novo Nordisk expects to increase diabetes medication prices; AbbVie expanded its Alzheimer's research
Interim results show cancer drug Imbruvica works well with other treatments; two studies show pricey new HCV medications are cost effective; the American College of Physicians wants less cardiac testing
The SEC said some company drug prices can be made public, 23andMe launched an R&D division, and Public Citizen is asking the FDA to withdraw a proposal it says will undermine drug safety information.
PBM Express Scripts said last year's trends reflect a major shift in how the pharmaceutical industry does business and that generics are not the bargain they once were.
HCV drugs and other specialty medications drove a 13% increase in last year's prescription spending, the CBO overestimated just how much healthcare reform would cost, and an FDA panel voted 17-0 in favor of Kythera's drug that can reduce double chins.
NICE greenlights Harvoni for Britain's national formulary, Pacira received a CRL instead of an expanded indication and Novo's latest diabetes outreach focuses on patients instead of drug brands.
Drugmakers face increasing pressure on pricing from insurers and PBMs.
Doctors want the National Health Service to allow them to prescribe the oncology drug for wet age-related macular degeneration.
Assemblyman David Chiu's bill would publish a drug's R&D and related costs.
An NIH study shows possible limit to Lucentis's appeal.
CVS health execs write that cost of long-term specialty medications, not short-timers like Sovaldi, are a major worry.
The reason: higher prices and more services.
The health minister is threatening price-related legislation.
Centers for Medicare and Medicaid Services says it is too early to blame a sluggish economy for slow growth.
AbbVie's deal with the PBM Express Scripts has altered the dynamic in hepatitis C price-setting, writes Bloomberg.
More cost data for the file the latest data shows that up-front healthcare costs are prompting many patients to delay office visits.
The IMS Institute for Healthcare Informatics notes that developed markets remain a key driver.
The deal will cap the monthly price some patients may pay for medications such as Atripla.
Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.